LinkedIn

 آمار

تعداد نشریات21
تعداد شماره‌ها1,199
تعداد مقالات10,937
تعداد مشاهده مقاله73,824,064
تعداد دریافت فایل اصل مقاله34,270,476
Mirzaeyan, Fatemeh, Chahardouli, Bahram, Mirzaeian, Amin, Alizad Ghandforoush, Nasrin, Alimoghaddam, Kamran, Rostami, Shahrbano. (1400). Concurrent Evaluation of the Expression and Methylation of Secreted Frizzled-Related Protein 2 along with Beta-Catenin Expression in Patients with non-M3 Acute Myeloid Leukemia. سامانه مدیریت نشریات علمی, 46(3), 180-188. doi: 10.30476/ijms.2020.84316.1396
Fatemeh Mirzaeyan; Bahram Chahardouli; Amin Mirzaeian; Nasrin Alizad Ghandforoush; Kamran Alimoghaddam; Shahrbano Rostami. "Concurrent Evaluation of the Expression and Methylation of Secreted Frizzled-Related Protein 2 along with Beta-Catenin Expression in Patients with non-M3 Acute Myeloid Leukemia". سامانه مدیریت نشریات علمی, 46, 3, 1400, 180-188. doi: 10.30476/ijms.2020.84316.1396
Mirzaeyan, Fatemeh, Chahardouli, Bahram, Mirzaeian, Amin, Alizad Ghandforoush, Nasrin, Alimoghaddam, Kamran, Rostami, Shahrbano. (1400). 'Concurrent Evaluation of the Expression and Methylation of Secreted Frizzled-Related Protein 2 along with Beta-Catenin Expression in Patients with non-M3 Acute Myeloid Leukemia', سامانه مدیریت نشریات علمی, 46(3), pp. 180-188. doi: 10.30476/ijms.2020.84316.1396
Mirzaeyan, Fatemeh, Chahardouli, Bahram, Mirzaeian, Amin, Alizad Ghandforoush, Nasrin, Alimoghaddam, Kamran, Rostami, Shahrbano. Concurrent Evaluation of the Expression and Methylation of Secreted Frizzled-Related Protein 2 along with Beta-Catenin Expression in Patients with non-M3 Acute Myeloid Leukemia. سامانه مدیریت نشریات علمی, 1400; 46(3): 180-188. doi: 10.30476/ijms.2020.84316.1396

Concurrent Evaluation of the Expression and Methylation of Secreted Frizzled-Related Protein 2 along with Beta-Catenin Expression in Patients with non-M3 Acute Myeloid Leukemia

Iranian Journal of Medical Sciences
مقاله 4، دوره 46، شماره 3، مرداد 2021، صفحه 180-188    اصل مقاله (1.04 M)
نوع مقاله: Original Article(s)
شناسه دیجیتال (DOI): 10.30476/ijms.2020.84316.1396
نویسندگان
Fatemeh Mirzaeyan1؛ Bahram Chahardouli2؛ Amin Mirzaeian3؛ Nasrin Alizad Ghandforoush2؛ Kamran Alimoghaddam2؛ Shahrbano Rostami* 2
1Department of Hematology and Blood Banking, School of Allied Medicine, Tehran University of Medical Sciences, Tehran, Iran
2Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran
3Department of Immunology, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran
چکیده
Background: Wnt signaling is a critical pathway for the development of acute myeloid leukemia (AML). Some studies have evaluated the expression or methylation of secreted frizzled-related protein 2 (SFRP2) as an antagonist and beta-catenin (β-catenin) as a critical mediator of this pathway. Since we found no comprehensive study on these genes in Iran, we aimed to investigate the status of both SFRP2 expression and methylation, and also β-catenin expression, in conjunction with clinical characteristics, in Iranian patients with de novo non-M3 AML.
Methods: The methylation and expression of SFRP2 were determined in 188 patients with primary non-M3 AML and 60 healthy controls, who were referred to Shariati Hospital, Tehran, Iran, between January 2017 and February 2019. The methylation-specific polymerase chain reaction (PCR) and real-time quantitative PCR were used, respectively. The expression of β-catenin was explored via real-time quantitative PCR. Statistical analysis was performed using the Mann–Whitney U test (SPSS software, version 23). A P value of less than 0.05 (2-tailed) was considered significant.
Results: SFRP2 mRNA showed a significant decline in the AML group compared with the controls (p <0.001). The hypermethylation of the SFRP2 promoter occurred in 25.5% (48/188) of the cases. SFRP2 expression exhibited a negative correlation with the white blood cell count (P=0.003). The expression of β-catenin increased significantly in the patients in comparison with the controls (p <0001), and a significant difference was observed between the patients, who achieved complete remission and those, who did not (P=0.046).
Conclusion: The findings of this study showed that alterations in SFRP2 and β-catenin expression can be used as a potential biomarker for differentiating patients with new non-M3 AML from the controls. Additionally, an evaluation of β-catenin expression may be valuable in predicting complete remission in patients with non-M3 AML.
کلیدواژه‌ها
SFRP2 protein؛ Humans؛ Leukemia؛ Myeloid؛ Acute؛ beta Catenin؛ Wnt signaling pathway
سایر فایل های مرتبط با مقاله
مراجع
  1. Grove CS, Vassiliou GS. Acute myeloid leukaemia: a paradigm for the clonal evolution of cancer? Dis Model Mech. 2014;7:941-51. doi: 10.1242/dmm.015974. PubMed PMID: 25056697; PubMed Central PMCID: PMCPMC4107323.
  2. Siveen KS, Uddin S, Mohammad RM. Targeting acute myeloid leukemia stem cell signaling by natural products. Mol Cancer. 2017;16:13. doi: 10.1186/s12943-016-0571-x. PubMed PMID: 28137265; PubMed Central PMCID: PMCPMC5282735.
  3. Goldman SL, Hassan C, Khunte M, Soldatenko A, Jong Y, Afshinnekoo E, et al. Epigenetic Modifications in Acute Myeloid Leukemia: Prognosis, Treatment, and Heterogeneity. Front Genet. 2019;10:133. doi: 10.3389/fgene.2019.00133. PubMed PMID: 30881380; PubMed Central PMCID: PMCPMC6405641.
  4. Kostroma, II, Gritsaev SV, Sidorova ZY, Tiranova SA, Svitina SP, Drizhun YS, et al. Aberrant methylation of the promoter regions of the SOX7 and p15INK4b genes and Wnt signaling pathway antagonists in patients with acute myeloid leukemias. Ter Arkh. 2016;88:31-6. doi: 10.17116/terarkh201688731-36. PubMed PMID: 27459612.
  5. Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer. 2008;8:387-98. doi: 10.1038/nrc2389. PubMed PMID: 18432252.
  6. Valencia A, Roman-Gomez J, Cervera J, Such E, Barragan E, Bolufer P, et al. Wnt signaling pathway is epigenetically regulated by methylation of Wnt antagonists in acute myeloid leukemia. Leukemia. 2009;23:1658-66. doi: 10.1038/leu.2009.86. PubMed PMID: 19387464.
  7. Grainger S, Traver D, Willert K. Wnt Signaling in Hematological Malignancies. Prog Mol Biol Transl Sci. 2018;153:321-41. doi: 10.1016/bs.pmbts.2017.11.002. PubMed PMID: 29389522; PubMed Central PMCID: PMCPMC5972548.
  8. Wang H, Fan R, Wang XQ, Wu DP, Lin GW, Xu Y, et al. Methylation of Wnt antagonist genes: a useful prognostic marker for myelodysplastic syndrome. Ann Hematol. 2013;92:199-209. doi: 10.1007/s00277-012-1595-y. PubMed PMID: 23093371.
  9. Veeck J, Bektas N, Hartmann A, Kristiansen G, Heindrichs U, Knuchel R, et al. Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours. Breast Cancer Res. 2008;10:R82. doi: 10.1186/bcr2151. PubMed PMID: 18826564; PubMed Central PMCID: PMCPMC2614517.
  10. Zhan T, Rindtorff N, Boutros M. Wnt signaling in cancer. Oncogene. 2017;36:1461-73. doi: 10.1038/onc.2016.304. PubMed PMID: 27617575; PubMed Central PMCID: PMCPMC5357762.
  11. Rao TP, Kuhl M. An updated overview on Wnt signaling pathways: a prelude for more. Circ Res. 2010;106:1798-806. doi: 10.1161/CIRCRESAHA.110.219840. PubMed PMID: 20576942.
  12. Majchrzak-Celinska A, Slocinska M, Barciszewska AM, Nowak S, Baer-Dubowska W. Wnt pathway antagonists, SFRP1, SFRP2, SOX17, and PPP2R2B, are methylated in gliomas and SFRP1 methylation predicts shorter survival. J Appl Genet. 2016;57:189-97. doi: 10.1007/s13353-015-0312-7. PubMed PMID: 26337424; PubMed Central PMCID: PMCPMC4830852.
  13. Chiurillo MA. Role of the Wnt/beta-catenin pathway in gastric cancer: An in-depth literature review. World J Exp Med. 2015;5:84-102. doi: 10.5493/wjem.v5.i2.84. PubMed PMID: 25992323; PubMed Central PMCID: PMCPMC4436943.
  14. Ren J, Jian F, Jiang H, Sun Y, Pan S, Gu C, et al. Decreased expression of SFRP2 promotes development of the pituitary corticotroph adenoma by upregulating Wnt signaling. Int J Oncol. 2018;52:1934-46. doi: 10.3892/ijo.2018.4355. PubMed PMID: 29620167; PubMed Central PMCID: PMCPMC5919716.
  15. Griffiths EA, Gore SD, Hooker C, McDevitt MA, Karp JE, Smith BD, et al. Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation. Leuk Lymphoma. 2010;51:1711-9. doi: 10.3109/10428194.2010.496505. PubMed PMID: 20795789; PubMed Central PMCID: PMCPMC4000011.
  16. Cheng CK, Li L, Cheng SH, Ng K, Chan NP, Ip RK, et al. Secreted-frizzled related protein 1 is a transcriptional repression target of the t(8;21) fusion protein in acute myeloid leukemia. Blood. 2011;118:6638-48. doi: 10.1182/blood-2011-05-354712. PubMed PMID: 22031861.
  17. Tickenbrock L, Schwable J, Wiedehage M, Steffen B, Sargin B, Choudhary C, et al. Flt3 tandem duplication mutations cooperate with Wnt signaling in leukemic signal transduction. Blood. 2005;105:3699-706. doi: 10.1182/blood-2004-07-2924. PubMed PMID: 15650056.
  18. Jiang J, Griffin JD. Wnt/beta-catenin Pathway Modulates the Sensitivity of the Mutant FLT3 Receptor Kinase Inhibitors in a GSK-3beta Dependent Manner. Genes Cancer. 2010;1:164-76. doi: 10.1177/1947601910362446. PubMed PMID: 21779446; PubMed Central PMCID: PMCPMC3092187.
  19. Jost E, Schmid J, Wilop S, Schubert C, Suzuki H, Herman JG, et al. Epigenetic inactivation of secreted Frizzled-related proteins in acute myeloid leukaemia. Br J Haematol. 2008;142:745-53. doi: 10.1111/j.1365-2141.2008.07242.x. PubMed PMID: 18537968.
  20. Naing NN. Determination of sample size. Malays J Med Sci. 2003;10:84-6. PubMed PMID: 23386802; PubMed Central PMCID: PMCPMC3561892.
  21. Ghasemi A, Rostami S, Chahardouli B, Alizad Ghandforosh N, Ghotaslou A, Nadali F. Study of SFRP1 and SFRP2 methylation status in patients with de novo Acute Myeloblastic Leukemia. Int J Hematol Oncol Stem Cell Res. 2015;9:15-21. PubMed PMID: 25802696; PubMed Central PMCID: PMCPMC4369229.
  22. Gharagozlou S, Kardar GA, Rabbani H, Shokri F. Molecular analysis of the heavy chain variable region genes of human hybridoma clones specific for coagulation factor VIII. Thromb Haemost. 2005;94:1131-7. doi: 10.1160/TH05-06-0445. PubMed PMID: 16411384.
  23. Asgarian Omran H, Shabani M, Shahrestani T, Sarafnejad A, Khoshnoodi J, Vossough P, et al. Immunophenotypic subtyping of leukemic cells from Iranian patients with acute lymphoblastic leukaemia: association to disease outcome. Iran J Immunol. 2007;4:15-25. PubMed PMID: 17652839.
  24. Ardestani MT, Kazemi A, Chahardouli B, Mohammadi S, Nikbakht M, Rostami S, et al. FLT3-ITD Compared with DNMT3A R882 Mutation Is a More Powerful Independent Inferior Prognostic Factor in Adult Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study. Turk J Haematol. 2018;35:158-67. doi: 10.4274/tjh.2018.0017. PubMed PMID: 29786546; PubMed Central PMCID: PMCPMC6110452.
  25. Shen JZ, Xu CB, Fu HY, Wu DS, Zhou HR, Fan LP. Methylation of secreted frizzled related protein gene in acute leukemia patients in China. Asian Pac J Cancer Prev. 2011;12:2617-21. PubMed PMID: 22320963.
  26. Guo H, Zhang TJ, Wen XM, Zhou JD, Ma JC, An C, et al. Hypermethylation of secreted frizzled-related proteins predicts poor prognosis in non-M3 acute myeloid leukemia. Onco Targets Ther. 2017;10:3635-44. doi: 10.2147/OTT.S136502. PubMed PMID: 28790854; PubMed Central PMCID: PMCPMC5530859.
  27. Guo H, Lin J, Wen XM, Yang J, Qian W, Deng ZQ, et al. Decreased SFRP2 expression is associated with intermediate and poor karyotypes in de novo acute myeloid leukemia. Int J Clin Exp Pathol. 2014;7:4695-703. PubMed PMID: 25197341; PubMed Central PMCID: PMCPMC4152031.
  28. Wang H, Duan XL, Qi XL, Meng L, Xu YS, Wu T, et al. Concurrent Hypermethylation of SFRP2 and DKK2 Activates the Wnt/beta-Catenin Pathway and Is Associated with Poor Prognosis in Patients with Gastric Cancer. Mol Cells. 2017;40:45-53. doi: 10.14348/molcells.2017.2245. PubMed PMID: 28152305; PubMed Central PMCID: PMCPMC5303888.
  29. Zhou H, Mak PY, Mu H, Mak DH, Zeng Z, Cortes J, et al. Combined inhibition of beta-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo. Leukemia. 2017;31:2065-74. doi: 10.1038/leu.2017.87. PubMed PMID: 28321124; PubMed Central PMCID: PMCPMC5628102.
  30. Ysebaert L, Chicanne G, Demur C, De Toni F, Prade-Houdellier N, Ruidavets JB, et al. Expression of beta-catenin by acute myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis. Leukemia. 2006;20:1211-6. doi: 10.1038/sj.leu.2404239. PubMed PMID: 16688229.
  31. Gandillet A, Park S, Lassailly F, Griessinger E, Vargaftig J, Filby A, et al. Heterogeneous sensitivity of human acute myeloid leukemia to beta-catenin down-modulation. Leukemia. 2011;25:770-80. doi: 10.1038/leu.2011.17. PubMed PMID: 21339756; PubMed Central PMCID: PMCPMC4289854.
  32. Yeung J, Esposito MT, Gandillet A, Zeisig BB, Griessinger E, Bonnet D, et al. beta-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell. 2010;18:606-18. doi: 10.1016/j.ccr.2010.10.032. PubMed PMID: 21156284.
  33. Siapati EK, Papadaki M, Kozaou Z, Rouka E, Michali E, Savvidou I, et al. Proliferation and bone marrow engraftment of AML blasts is dependent on beta-catenin signalling. Br J Haematol. 2011;152:164-74. doi: 10.1111/j.1365-2141.2010.08471.x. PubMed PMID: 21118196.
آمار
تعداد مشاهده مقاله: 4,800
تعداد دریافت فایل اصل مقاله: 2,975


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب